Open AccessThe adjuvant regimen for resected EGFR mutated patients: the “same-for-all-therapy” or not?
Author(s) -
Cesare Gridelli,
Francesca Casaluce
Publication year - 2020
Publication title -
annals of translational medicine
Language(s) - English
Resource type - Journals
eISSN - 2305-5847
pISSN - 2305-5839
DOI - 10.21037/atm-20-3170
Subject(s) - medicine , regimen , adjuvant therapy , adjuvant , oncology , bioinformatics , chemotherapy , biology
Division of Medical Oncology, A.O.R.N. San Giuseppe Moscati, Avellino, AV, Italy Correspondence to: Cesare Gridelli. Division of Medical Oncology, A.O.R.N. S.G. Moscati Hospital, Contrada Amoretta, 83100, Avellino, Italy. Email: cgridelli@libero.it. Provenance and Peer Review: This article was commissioned by the editorial office, Annals of Translational Medicine. The article did not undergo external peer review. Comment on: Liang W, Cai K, Chen C, et al. Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition). Transl Lung Cancer Res 2019;8:1163-73.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom